Liposomal Lactoferrin as Potential Preventative and Cure for COVID-19

Gabriel Serrano Sanmiguel¹, I. Kochergina¹, A. Albors², E. Diaz³, M. Oroval³, G. Hueso³, J.M. Serrano³

¹Dr. Serrano Dermatology Clinic, Valencia, Spain

²Medical Department of Sesderma Laboratories, Valencia, Spain

³Research Department of Sesderma Laboratories, Valencia, Spain

Aim: this study is aimed at evaluating the efficacy of bovine liposomal lactoferrin (LLF) for the treatment of COVID-19 on outpatient basis.

Patients and Methods: a prospective observational study was performed in 75 patients with typical symptoms of COVID-19 who tested positive to IgM/IgG rapid test. Patients were isolated and treated at home using remote systems, reviewed twice a day for 10 days, and followed up to 1 month. A liposomal bovine lactoferrin (LLF) nutritional syrup food supplement (32 mg of LF / 10 ml plus 12 mg of vitamin C) was administered orally in 4 to 6 doses per day for 10 days. In addition, a zinc solution was administered at the dose of 10 mg / 10 ml twice or three times a day. A control group of 12 patients who took only LLF was included. All family members in contact with patients (256 persons) were also treated with half of this dose.

Results: the most frequent symptoms in our patients were a very heavy sensation of tiredness or weakness (95%), alteration in the perception of smelling and taste (88%), cough (83%) and muscular pain (67%). Oral treatment with LLF and LLF + zinc solution allowed for significant improvement in 100% of patients within the first 4−5 days. Same treatment at lower dose prevented the disease in healthy persons directly related with the affected patients.

Conclusion: LF possess antiviral, immunomodulatory and anti-inflammatory effects which might be important for the treatment of COVID-19 infection. The authors concluded about the potential use of LLF for the prevention and treatment of COVID-19.

Keywords: COVID-19, liposomal bovine lactoferrin, viral infection, respiratory tract infection, prevention.